Jointown Pharmaceutical Group (02566.HK) announced the results of its IPO, with a public offering oversubscribed by 675.83 times, allotment rate of one lot (200 shares) at 20.01%, and subscribers of 4,000 shares successful in receiving one lot. The international offering was oversubscribed by 1.18 times. Under the clawback mechanism, the number of shares in the public offering has increased to 22.6994 million shares, accounting for 50% of the total offering. The final offer price is 12.42 yuan, raising a net amount of 0.485 billion yuan. Shares are expected to list on Thursday (28th).
Sino Biopharmaceutical company Jointown Pharmaceutical Group is globally issuing 45.3988 million shares, with the Hong Kong offering originally accounting for 10%; the price range of the IPO is between 11.48-12.56 yuan. Seven cornerstone investors include: Hengda Hong Kong, Fosun Pharma (02196.HK) subsidiary Fosun Industrial, Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) subsidiary King-Friend Hong Kong, Ali Health (00241.HK) subsidiary Ali Health Hong Kong, Jointown Pharmaceutical Group (600998.SH) subsidiary Jointown International, Junting Hotel (301073.SZ) founder Wu Qiyuan, and Delta Capital HK, collectively subscribing to 0.35 billion yuan of company shares.
